Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RestoratiVE303 phase 3 study in prevention of recurrent Clostridioides difficile infection
NL-OMON60834Phase 3Recruiting
- Sponsor
- Vedanta Biosciences
- Start
- Nov 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Clostridioides difficile colitis (CDI) and Clostridioides difficile infection recurrence (rCDI) comparing VE303 with Placebo (2 arms). Primary endpoint: CDI recurrence through Week 8. Started Nov 2024; status: recruiting.
02
Drugs
VE303
03
Conditions
Clostridioides difficile colitis (CDI)Clostridioides difficile infection recurrence (rCDI)
Beyond the preview
Go deeper on NL-OMON60834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60834.